69.00%70.00%Operating expenses growth For the Fiscal Year Ended 2011 FromTo Increase in operating expense on a GAAP basis
17.00%19.00%Share-based compensation expense
-1.00%-1.00%Amortization of intangibles
-0.70%-0.70%Levitronix transaction costs
-0.30%-0.30% Increase in operating expense on a non-GAAP basis
15.00%17.00%Net income per diluted share reconciliation For the Fiscal Year Ended 2011 FromToNet income per diluted share on a GAAP basis
.15Share-based compensation expense
0.180.18Amortization of purchased intangibles
0.090.09Impact of adoption of ASC 470-20
0.030.03Levitronix transaction costs
0.040.04Income tax effect of non-GAAP income before tax
0.010.01Net income per diluted share on a non-GAAP basis
.50Shares used in calculation of net income per diluted share --GAAP and non-GAAP
63,00063,000Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate LVAS and Thoratec VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate, HeartMate II and GoGear are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Levitronix Medical GmbH, which is being renamed as Thoratec Switzerland GmbH in connection with the transaction.
Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2011 financial results or future performance, contain forward-looking statements within the meaning of Secti
|SOURCE Thoratec Corporation|
Copyright©2010 PR Newswire.
All rights reserved